Is Troxerutin compatible with breastfeeding? Do we have alternatives for Troxerutin?

Troxerutin

January 7, 2018 (Very Low Risk)

Main component (>45%) of Oxerutins that are derived from a naturally occurring Bioflavonoid, Rutin.

Flavonoids are phenolic compounds naturally occurring that are abundantly present in plants and seaweed.

We take it from fruits, vegetables, tea and red wine (as a few examples)

Most important types are: anthocyanins, chalcons, flavonols, flavones, flavonoids and tannins. No risk for toxic nor side-effects in humans have been found.

They appear naturally in the breast milk in amounts related to mother's diet.

Attributed anti-oxidant activity and other properties that have not been fully shown yet (Martinez 2016, Morling 2015, Cohen 2012), as amelioration of capillary vessel function which is a reason to be used for treatment of venous insufficiency (varicose veins) and prevention of arteriosclerosis.

Alternatives

We do not have alternatives for Troxerutin since it is relatively safe.

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • Trihydroxyethylrutoside
  • Trioxyethylrutin
  • Vitamin P4

Writings

  • τροξερουτίνη (Greek)
  • تروكسيروتين (Arabic)
  • Троксерутин (Cyrillic)
  • 曲克芦丁 (Chinese)
  • トロキセルチン (Japanese)
  • Troxérutine (French)
  • C33H42O19 (Molecular formula)
  • 3′,4′,7-Tris[O-(2-hydroxyethyl)]rutin; 5-Hydroxy-7-(2-hydroxyethoxy)-2-[3,4-bis(2-hydroxyethoxy)phenyl]-4-oxo-4H-chromen-3-yl rutinoside (Chemical name)
  • C05CA04 (ATC Code/s)

Drug trade names

References

  1. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016Abstract
  2. Morling JR, Yeoh SE, Kolbach DN. Rutosides for treatment of post-thrombotic syndrome. Cochrane Database Syst Rev. 2015Abstract
  3. Song BJ, Jouni ZE, Ferruzzi MG. Assessment of phytochemical content in human milk during different stages of lactation. Nutrition. 2013Abstract Full text (link to original source) Full text (in our servers)
  4. Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest. 2012Abstract
  5. Troxerutina. Ficha técnica. 2011 Full text (in our servers)
  6. Kienzler JL, Sallin D, Schifflers MH, Ghika A. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers. Eur J Clin Pharmacol. 2002Abstract
  7. Dittrich P, Ostrowski J, Beubler E, Schraven E, Kukovetz W. [HPLC determination of troxerutin in plasma and urine following oral administration in man]. Arzneimittelforschung. 1985Abstract
  8. Krajnovic P. [The influence of the combination of coumarin and troxerutin on infantile blood parameter in lactation period. Short communication (author's transl)]. Arzneimittelforschung. 1977Abstract